Regardless of the sequential decrease in Current Liabilities, during the first quarter 2022, Quick Ratio deteriorated to 0.01 a new company low.

Within Major Pharmaceutical Preparations industry 540 other companies have achieved higher Quick Ratio than Musclepharm in first quarter 2022. While Quick Ratio total ranking has improved so far during the Q1 2022 to 5363, from total ranking in the fourth quarter 2021 at 5826.

Explain Quick Ratio?
How much Cash & cash equivalents MSLP�s has?
What are MSLP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MSLP Quick Ratio	(Mar 31 2022) Q1	(Dec 31 2021) Q4	(Sep 30 2021) Q3	(Jun 30 2021) Q2	(Mar 31 2021) Q1
Y / Y Current Liabilities Change	65.51 %	62.79 %	8.23 %	-18.65 %	-30.44 %
Y / Y Cash & cash equivalent Change	-9.8 %	-38.94 %	-64.61 %	-16.24 %	-4.21 %
Quick Ratio MRQ	0.01	0.02	0.01	0.03	0.02
MSLP's Total Ranking	# 5363	# 5826	# 6052	# 4796	# 5939
Seq. Current Liabilities Change	-11.51 %	46.67 %	13.68 %	12.19 %	-12.97 %
Seq. Cash & cash equivalent Change	-56.34 %	218.49 %	-62.2 %	71.62 %	-70.44 %

Quick Ratio first quarter 2022 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 541
Healthcare Sector	# 1117
Overall Market	# 5363

Quick Ratio Statistics
High	Average	Low
0.81	0.11	0.01
(Jun 30 2013)		(Sep 30 2021)

Financial Statements
Musclepharm's Current Liabilities	$ 48 Millions	Visit MSLP's Balance sheet
Musclepharm's Cash & cash equivalent	$ 1 Millions	Visit MSLP's Balance sheet
Source of MSLP's Sales		Visit MSLP's Sales by Geography

Cumulative Musclepharm's Quick Ratio

MSLP's Quick Ratio for the trailling 12 Months

MSLP Quick Ratio	(Mar 31 2022) 12 Months	(Dec 31 2021) 12 Months	(Sep 30 2021) 12 Months	(Jun 30 2021) 12 Months	(Mar 31 2021) 12 Months
Y / Y Current Liabilities TTM Growth	25.85 %	2.4 %	-13.17 %	-18.22 %	-21.58 %
Y / Y Cash & cash equivalent TTM Growth	-35.48 %	-34.64 %	-10.18 %	-4.28 %	2.15 %
Quick Ratio TTM	0.02	0.02	0.03	0.04	0.04
Total Ranking TTM	# 6011	# 6038	# 5569	# 3957	# 6035
Seq. Current Liabilities TTM Growth	12.44 %	15.87 %	2.18 %	-5.46 %	-8.51 %
Seq. Cash & cash equivalent TTM Growth	-1.8 %	-19.52 %	-14.93 %	-4.03 %	-0.53 %

Quick ratio ranking by company, industry and sector >> Back to MSLP Financial Strength Comparisons >> Go to Compare MSLP Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the fall in Current Liabilities in the Q1 2022 to $48.17 millions, cumulative Quick Ratio remained unchanged at 0.02 below the Musclepharm Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 620 other companies have achieved higher Quick Ratio than Musclepharm. While Quick Ratio overall ranking has improved so far to 6011, from total ranking during the twelve months ending fourth quarter 2021 at 6038.

Explain Quick Ratio?
How much Cash & cash equivalents MSLP�s has?
What are MSLP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 621
Healthcare Sector	# 1252
Within the Market	# 6011

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.4	0.11	0.02
(Sep. 30, 2013)

Companies with similar Quick Ratio in the quarter ending Mar 31 2022, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2022 MRQ Cash & cash equivalent	Mar 31 2022 MRQ Current Liabilities
Integrated Biopharma Inc	0.03	$ 0.264 Millions	$ 9.233 Millions
Emmaus Life Sciences Inc	0.02	$ 0.813 Millions	$ 34.551 Millions
Kaya Holdings Inc	0.02	$ 0.203 Millions	$ 8.769 Millions
Provectus Biopharmaceuticals Inc	0.02	$ 0.174 Millions	$ 7.825 Millions
Statera Biopharma Inc fka Cytocom Inc	0.02	$ 0.331 Millions	$ 15.073 Millions
Wellness Center Usa Inc	0.02	$ 0.064 Millions	$ 2.959 Millions
Q Biomed inc	0.02	$ 0.137 Millions	$ 6.368 Millions
Avenir Wellness Solutions Inc	0.02	$ 0.531 Millions	$ 25.060 Millions
Evofem Biosciences Inc	0.02	$ 2.761 Millions	$ 154.474 Millions
Sunwin Stevia International Inc.	0.01	$ 0.321 Millions	$ 22.005 Millions
Novaccess Global Inc	0.01	$ 0.062 Millions	$ 4.516 Millions
Actavia Life Sciences Inc	0.01	$ 0.028 Millions	$ 2.174 Millions
Cytodyn inc	0.01	$ 1.363 Millions	$ 106.532 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.098 Millions	$ 8.555 Millions
Musclepharm Corporation	0.01	$ 0.534 Millions	$ 48.171 Millions
Skinvisible Inc	0.01	$ 0.025 Millions	$ 3.067 Millions
Earth Science Tech Inc	0.01	$ 0.027 Millions	$ 3.499 Millions
Rapid Therapeutic Science Laboratories Inc	0.01	$ 0.033 Millions	$ 5.124 Millions
REGENEREX PHARMA, INC.	0.01	$ 0.003 Millions	$ 0.437 Millions
American Bio Medica Corporation	0.01	$ 0.017 Millions	$ 2.871 Millions
Cannapharmarx Inc	0.01	$ 0.080 Millions	$ 14.562 Millions
Moonlake Immunotherapeutics	0.00	$ 0.023 Millions	$ 5.948 Millions
Regen Biopharma Inc	0.00	$ 0.302 Millions	$ 77.380 Millions
Nanomix Corp	0.00	$ 0.011 Millions	$ 3.785 Millions

Date modified: 2026-09-08T15:10:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.